Proamatine and Omniscan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Proamatine (midodrine hydrochloride) and Omniscan (gadodiamide). Common drug interactions include nephrogenic systemic fibrosis among females and nephrogenic systemic fibrosis among males.

The phase IV clinical study analyzes what interactions people have when they take Proamatine and Omniscan. It is created by eHealthMe based on reports of 15 people who take the same drugs from the FDA, and is updated regularly.

What is Proamatine?

Proamatine has active ingredients of midodrine hydrochloride. It is often used in hypotension. eHealthMe is studying from 968 Proamatine users. Check the latest studies of Proamatine.

What is Omniscan?

Omniscan has active ingredients of gadodiamide. eHealthMe is studying from 6,169 Omniscan users. Check the latest studies of Omniscan.

On Jul, 20, 2026

15 people who take Proamatine and Omniscan together, and have interactions are studied.

Proamatine and Omniscan drug interactions.

What are the common drug interactions of Proamatine and Omniscan, by gender? *:

female:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Joint range of motion decreased (disease of joint movement)
Anxiety
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)
Oedema peripheral (superficial swelling)
Pain
Skin hypertrophy (skin cells enlarges)
Arthralgia (joint pain)
Asthenia (weakness)
Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)

male:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Deformity (disfigurement)
Joint range of motion decreased (disease of joint movement)
Mobility decreased (ability to move is reduced)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Rash macular (small, flat red spots)
Rash papular (redness with papule)
Skin induration (an abnormally hard spot or area on the skin)
Skin plaque (red, scaly patches to appear on the skin)
Skin tightness

What are the common drug interactions of Proamatine and Omniscan, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Deformity (disfigurement)
Erythema (redness of the skin)
Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Pain
Rash
Rash papular (redness with papule)
Scar
Septic shock (shock due to blood infection)
Skin atrophy (wasting of skin)
Skin exfoliation (removal of the oldest dead skin cells)

40-49:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)
General physical health deterioration (weak health status)
Oedema peripheral (superficial swelling)
Skin hypertrophy (skin cells enlarges)
Skin induration (an abnormally hard spot or area on the skin)
Arthralgia (joint pain)
Asthenia (weakness)
Deformity (disfigurement)
Erythema (redness of the skin)

50-59:

Anxiety
Joint range of motion decreased (disease of joint movement)
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)
Hypertonia (abnormal increase in muscle tension and a reduced ability of a muscle to stretch)
Mitral valve replacement
Mobility decreased (ability to move is reduced)
Muscle tightness
Muscular weakness (muscle weakness)
Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
Oedema peripheral (superficial swelling)

60+:

n/a

What are the existing conditions these people have? *

Nuclear Magnetic Resonance Imaging Abdominal: 10 people, 66.67%
Nuclear Magnetic Resonance Imaging Brain: 8 people, 53.33%
Renal Mass (mass in kidney): 2 people, 13.33%
Pressure Ulcer: 2 people, 13.33%
Osteomyelitis (infection of bone): 2 people, 13.33%
Neck Pain: 2 people, 13.33%
Liver Disorder (liver diseases): 2 people, 13.33%
Venous Occlusion (the blocking of venous return): 1 person, 6.67%
Kidney Transplant Rejection: 1 person, 6.67%
Infection: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Proamatine and Omniscan?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously